Insulet advertising spend, FY2025
Insulet (PODD) reported $121M of advertising expense for the fiscal year ended Dec 31, 2025. That is 4.5% of revenue of $2.7B. Up 43.9% from FY2024.
Key facts
- Ad spend is 4.0x its FY2020 level ($30M), faster than revenue (3.0x).
- FY2025 is the highest year on file, going back to FY2018.
- Largest increase +167.9% in FY2020; largest cut -6.6% in FY2022.
- Ad spend has risen 3 years in a row.
- Ad spend is 4.5% of revenue, up from 3.3% in FY2020.
- Insulet spends more on advertising than 33% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is close to the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 10.4% of selling, general and administrative expense. Research and development spending was 2.5x advertising. Advertising equalled 25.6% of operating income.
| Advertising | $121M | AdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $1.2B | ad spend = 10.4% |
| Research and development | $301M | R&D = 2.5x ad spend |
| Operating income | $474M | ad spend = 25.6% |
| Net income | $247M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121M | +43.9% | $2.7B | 4.5% | AdvertisingExpense | 10-K Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $84.3M | +33.6% | $2.1B | 4.1% | AdvertisingExpense | 10-K Feb 18, 2026 |
| FY2023 | Dec 31, 2023 | $63.1M | +53.2% | $1.7B | 3.7% | AdvertisingExpense | 10-K Feb 18, 2026 |
| FY2022 | Dec 31, 2022 | $41.2M | -6.6% | $1.3B | 3.2% | AdvertisingExpense | 10-K Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | $44.1M | +47.0% | $1.1B | 4.0% | AdvertisingExpense | 10-K Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $30M | +167.9% | $904M | 3.3% | AdvertisingExpense | 10-K Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $11.2M | +6.7% | $738M | 1.5% | AdvertisingExpense | 10-K Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | $10.5M | n/a | $564M | 1.9% | AdvertisingExpense | 10-K Feb 24, 2021 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Insulet in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 305 | Generac | $123M | 2.9% | +5.7% | FY2025 |
| 306 | Lyft | $123M | 1.9% | -10.2% | FY2025 |
| 307 | Snowflake | $122M | 2.6% | +16.3% | FY2026 |
| 308 | Insulet | $121M | 4.5% | +43.9% | FY2025 |
| 309 | Tarsus Pharmaceuticals | $121M | 26.9% | +306.7% | FY2025 |
| 310 | Ziff Davis | $119M | 8.2% | +4.0% | FY2025 |
| 311 | Cisco Systems | $119M | 0.2% | -36.0% | FY2026 |
Questions
How much does Insulet spend on advertising?
Insulet spent $121M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 18, 2026.
What percentage of revenue does Insulet spend on advertising?
4.5% of revenue in fiscal 2025 ($121M against $2.7B). The median across the 458 companies tracked is 4.5%.
Is Insulet spending more on advertising?
Yes. Ad spend rose 43.9% in fiscal 2025 from fiscal 2024. It has risen 3 years in a row.
How does Insulet rank by advertising spend?
#308 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Insulet spend more on advertising than on R&D?
No. In fiscal 2025 it spent $301M on research and development and $121M on advertising.
What does Insulet's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 18, 2026
- Accession number
0001145197-26-000028- Company
- INSULET CORP, CIK 1145197, SIC 3841 (Surgical & Medical Instruments & Apparatus)
- Headquarters
- Acton, MA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Insulet advertising spend, FY2018-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 18, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/insulet/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies